| Antibody Drug Conjugates |
Merck R&D facility
Cancer-Associated Fusion Events
|e-Newsletter || www.pharmafocusasia.com | Archives | Advertise || |
| || |
|Articles || |
|Antibody Drug Conjugates in Reducing Disease Burden |
Antibody Drug Conjugates provide a high level of promise, and hence there will be a conscious effort to expand the application(s) of this technology to disease indications beyond oncology provide a high level of promise, and hence there will be a conscious effort to expand the application of this technology to disease indications beyond oncology....
|Future Pharma |
Pharmaceuticals play a critical role in improving human and animal health and well-being. They bring tremendous benefits to public health and economic productivity by saving lives, increasing life spans, reducing suffering, preventing surgeries, and even reducing hospital stays...
|Projects || |
|Merck Serono to invest €65 million for Biopharmaceutical R&D facility expansion in Germany |
Merck Serono, the biopharmaceutical business of Merck, announced the expansion of its R&D facility in Darmstadt, Germany with an investment of €65 million.Merck is investing €65 million in a new laboratory building that will span more than 16,000 square meters and accommodate...
|Research Insights || |
|FARE-CAFE: a database of functional and regulatory elements of cancer-associated fusion events |
Chromosomal translocation (CT) is of enormous clinical interest because this disorder is associated with various major solid tumors and leukemia. A tumor-specific fusion gene event may occur when a translocation joins two separate genes. Currently, various CT databases provide...
|e-Magazine| Subscribe | Unsubscribe || |
|www.pharmafocusasia.com – a product of Ochre Media Pvt. Ltd. |
Ochre Media Pvt Ltd. Media Resource Centre, 2nd Floor, Oxford Plaza, Secunderabad - 500 003, Telangana, India
Tel: +91 40 4961 4567 | Fax: +91 40 4961 4555